Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June 2025—matching the monthly run rate of Mounjaro (tirzepatide), which posted ...

Novo Nordisk has launched Wegovy, a once-weekly weight-loss injection, in India. The drug aims to manage obesity and reduce heart risks amid the country's growing obesity crisis. Wegovy, which has ...

Zepbound and Wegovy are approved for weight loss and weight management in certain adults. Other drugs, such as Rybelsus, Ozempic, and Mounjaro, are not approved for this purpose but may be ...

Novo Nordisk’s arch-rival in the obesity market is Eli Lilly LLY. NVO’s Ozempic and Wegovy face strong competition from Lilly’s tirzepatide medicines, Mounjaro (T2D) and Wegovy (obesity).

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500.

Ozempic blindness isn’t a real diagnosis. It’s a nickname used to describe sudden vision loss that may be linked to the weight loss drugs semaglutide (Ozempic, Wegovy) and tirzepatide ...

GLP-1 agonists — including semaglutides like Ozempic and Wegovy and tirzepatides like Mounjaro and Zepbound — are intended to treat type 2 diabetes and obesity.

NEW YORK, May 20 (Reuters) - Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's (NOVOb.CO) Wegovy as the U.S. drugs regulator clamps down on ...

All participants were taking a weight loss medication: semaglutide (Ozempic or Wegovy), dulaglutide (Trulicity), or tirzepatide (Zepbound or Mounjaro). The majority (nearly 70 percent) were taking ...

A number of patients, including at least three from Long Island, contend they suddenly lost their vision after taking the widely popular weight loss drugs Ozempic and Wegovy, according to a Long ...